We are live on ! Find out more
ADMS

Adamas Pharmaceuticals
ADMS

Delisted

ADMS was delisted on the 23rd of November, 2021.

Back to rankings

73 hedge funds and large institutions have $146M invested in Adamas Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 26 increasing their positions, 17 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more capital invested

Capital invested by funds: $62M → $146M (+$83.8M)

73% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 11

53% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 17

20% more call options, than puts

Call options by funds: $830K | Put options by funds: $689K

12% more funds holding

Funds holding: 65 → 73 (+8)

Holders
73
Holders Change
+8
Holders Change %
+12.31%
% of All Funds
1.28%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
19
Increased
26
Reduced
17
Closed
11
Calls
$830K
Puts
$689K
Net Calls
+$141K
Net Calls Change
+$191K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$26.8M
2
SCM
Stonepine Capital Management
Oregon
+$13.6M
3
APM
Avidity Partners Management
Texas
+$11.5M
4
Swedbank
Swedbank
Sweden
+$7.75M
5
ACM
AIGH Capital Management
Maryland
+$6.97M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$4.01M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.66M
3
Deutsche Bank
Deutsche Bank
Germany
-$1.66M
4
DAM
Deltec Asset Management
New York
-$1.23M
5
EIM
Essex Investment Management
Massachusetts
-$1.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
DA
26
DCF Advisers
Connecticut
$768K +$672K +128,764 +412%
BBA
27
Baker Bros. Advisors
New York
$710K – – –
Millennium Management
28
Millennium Management
New York
$704K +$766K +146,750 New
Assenagon Asset Management
29
Assenagon Asset Management
Luxembourg
$593K -$11.6K -2,221 -2%
HVC
30
Healthcare Value Capital
New Jersey
$480K – – –
MFW
31
Mosaic Family Wealth
Missouri
$438K -$2.57K -493 -0.5%
Northern Trust
32
Northern Trust
Illinois
$427K +$107K +20,412 +30%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$409K -$14.6K -2,796 -3%
T. Rowe Price Associates
34
T. Rowe Price Associates
Maryland
$306K – – –
Squarepoint
35
Squarepoint
New York
$276K +$92.2K +17,662 +44%
Citadel Advisors
36
Citadel Advisors
Florida
$204K +$222K +42,546 New
ECM
37
ExodusPoint Capital Management
New York
$190K +$207K +39,618 New
Grantham, Mayo, Van Otterloo & Co (GMO)
38
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$189K +$206K +39,400 New
Fisher Asset Management
39
Fisher Asset Management
Washington
$180K +$7.01K +1,342 +4%
Deutsche Bank
40
Deutsche Bank
Germany
$179K -$1.66M -317,859 -90%
SG Americas Securities
41
SG Americas Securities
New York
$164K -$522 -100 -0.3%
SFI
42
Susquehanna Fundamental Investments
Pennsylvania
$152K -$95.2K -18,240 -37%
LSA
43
Leonteq Securities AG
Switzerland
$144K – – –
Goldman Sachs
44
Goldman Sachs
New York
$120K -$72.2K -13,836 -36%
ZCM
45
Zebra Capital Management
Connecticut
$112K +$122K +23,400 New
GCP
46
GSA Capital Partners
United Kingdom
$101K +$110K +21,013 New
CHAM
47
Clear Harbor Asset Management
Connecticut
$98K +$1.57K +300 +1%
Charles Schwab
48
Charles Schwab
California
$86K – – –
State Street
49
State Street
Massachusetts
$78K +$8.36K +1,600 +11%
California Public Employees Retirement System
50
California Public Employees Retirement System
California
$77K – – –
1
2
3 4

ADMS Hedge Fund Activity: Q1 2021 in Review

73 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q1 2021, worth a combined $146M — up 135% from $62M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ADMS positions and 11 closed out — a net gain of 8 holders — while 26 added to existing stakes and 17 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $26.8M. The largest seller was Morgan Stanley, cutting an estimated $4.01M.

  • 73 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q1 2021, up from 65 in Q4 2020.
  • Funds reported $146M of Adamas Pharmaceuticals stock for Q1 2021, up 135% quarter-over-quarter.
  • 19 funds opened new Adamas Pharmaceuticals positions in Q1 2021 and 11 closed out, a net change of +8 holders.
  • The largest Adamas Pharmaceuticals buyer in Q1 2021 was Fidelity Investments, an estimated $26.8M added.
  • The largest Adamas Pharmaceuticals seller in Q1 2021 was Morgan Stanley, an estimated $4.01M sold.

Based on aggregated 13F filings for Q1 2021.